AI PRICE FORECAST
IDXX Stock Forecast & AI Price Prediction
IDEXX Laboratories · Healthcare · Diagnostics & Research
IDXX live signal snapshot
Shares of IDXX were last at $702.59, up 0.85% on the day, trading 8.8% below its 52-week high of $769.98 and 40.3% above its 52-week low of $500.61. Stock Pulse 247's AI model currently rates IDXX a BUY, at 81% model confidence. The short-term averages line up bullishly, and the price is holding above its 50-day line. Its one-month projection is about $725.59, a 3.3% move from the last price.
IDXX's 14-day RSI is 74.9 — overbought territory, where short-term pullbacks or consolidation are common. The MACD indicator sits over its signal line, and the histogram reading of 10.75 shows buying pressure building. Its 50-day average ($555.73) remains 2.9% below the 200-day ($572.16), the pattern chartists call a death cross.
12 Wall Street analysts covering IDXX put the average price target at $717.17 (range $470.00–$810.00), implying 2.1% upside from the current price. The current recommendation trend leans bullish: 9 Buy/Strong Buy ratings vs 1 Sell/Strong Sell (and 4 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive IDXX dashboard for numbers updated throughout today's session.
About IDEXX Laboratories
IDEXX Laboratories, Inc. (IDXX) is a diagnostics & research company in the healthcare sector, headquartered in Westbrook, ME, United States. IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It has a market value of about $55.4 billion and roughly 11,000 full-time employees. With a beta of 1.54, the stock has historically swung more than the overall market.
IDXX performance vs. the market
IDXX is up 3.9% so far in 2026, behind the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has lost 1.0%, 12.5 points worse than the S&P 500. Its +35.0% move over the past month extends a +23.9% three-month run.
| Period | IDXX | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +35.0% | +11.4% | −2.3% |
| 3 months | +23.9% | +12.2% | −2.3% |
| Year to date | +3.9% | +22.1% | +11.4% |
| 1 year | −1.0% | +28.3% | +11.5% |
IDEXX Laboratories financials at a glance
IDEXX Laboratories's most recent quarter (ended Sep 30, 2026) brought in $1.2 billion of revenue and net income of $317 million (a 26.1% net margin). Revenue was up 9.9% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 47.3 on trailing earnings of $14.84 per share. Trailing free cash flow was $1.1 billion, and total debt equals 52% of shareholders' equity.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $1.2B | $317M |
| Jun 30, 2026 | $1.2B | $338M |
| Mar 31, 2026 | $1.1B | $278M |
| Dec 31, 2025 | $1.1B | $248M |
IDXX vs. its peers
IDXX's +3.9% this year ranks ahead of 1 of the 5 big healthcare names below. The strongest of the group this year is Eli Lilly and (LLY, +33.7%).
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| IDEXX Laboratories (IDXX) | $702.59 | +3.9% | 47.3 | BUY |
| Thermo Fisher Scientific (TMO) | $717.71 | +23.9% | 37.9 | BUY |
| Danaher (DHR) | $235.31 | +2.8% | 39.0 | BUY |
| Agilent Technologies (A) | $176.95 | +30.0% | 34.9 | BUY |
| IQVIA Holdings (IQV) | $274.53 | +21.8% | 33.4 | BUY |
| Eli Lilly and (LLY) | $1,437.29 | +33.7% | 46.7 | BUY |
IDXX stock: common questions
What is the IDXX stock price target?
12 Wall Street analysts put the average 12-month target at $717.17, in a range of $470.00–$810.00, versus a recent price of $702.59. Stock Pulse 247's model projects about $725.59 over the next month.
Is IDXX a buy right now?
Our AI model currently rates IDXX a BUY at 81% confidence. Among analysts, 9 rate it Buy or Strong Buy, 4 Hold and 1 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has IDXX stock performed this year?
IDXX is up 3.9% so far in 2026, behind the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has lost 1.0%, 12.5 points worse than the S&P 500. Its +35.0% move over the past month extends a +23.9% three-month run.
What is IDXX's 52-week high and low?
IDXX has traded between $500.61 and $769.98 over the past 52 weeks; at $702.59 it is 8.8% below its 52-week high of $769.98 and 40.3% above its 52-week low of $500.61.
What sector is IDXX in, and who are its peers?
IDXX is in the healthcare sector (diagnostics & research). Its largest peers on Stock Pulse 247 include Thermo Fisher Scientific (TMO), Danaher (DHR), Agilent Technologies (A), IQVIA Holdings (IQV).
How accurate is the IDXX forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines IDXX's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.